$SBC

SBC Medical Group Holdings Inc. (Nasdaq: SBC) is developing a DNA test to measure biological age using DNA methylation analysis. The test aims to provide insights into physical health beyond chronological age, with development led by subsidiary SBC AI Longevity Innovation Inc. SBC shares fell 1.4% to $5.46, with a market cap of $562 million.

Emerging Growth Research released an updated quarterly report on SBC Medical Group Holdings Inc. (NASDAQ:SBC), highlighting 13% YoY revenue growth to $49.2M in Q2:26, improved profitability, AI-driven initiatives, and global expansion. The company reported $185M in cash and $38M in debt, with a Debt/Book Equity ratio of 14%.

SBC Medical Group reported a 32% EBITDA surge in Q2, with Gorilla Clinic's transaction value up 19% YoY to $62M. The company is expanding non-aesthetic healthcare, using AI for efficiency, and pursuing M&A. It expects $15M in annual service-fee increases. SBC is also advancing U.S. and Southeast Asia expansion, with plans for a longevity center in Japan. The company has $184M in cash for growth and M&A, aiming for steady EPS growth.

SBC Medical Group Holdings (NASDAQ: SBC) reported Q2FY26 revenue of $49.2M, up 13% YoY, and operating profit growth of 30%. The company attributed the growth to franchise fee normalization and the inclusion of Waqoo operations. SBC has $185M in cash and $38M in debt, with plans for AI integration and global expansion.

Emerging Growth Research released an updated Q2:26 report on SBC Medical Group Holdings Inc. (NASDAQ:SBC), highlighting 13% revenue growth to $49.2M, 30% operating profit increase, AI-driven initiatives, and global expansion. SBC has $185M in cash and $38M in debt. The report is company-sponsored, with EGR disclosing a $25,000 payment from SBC.

SBC Medical Group Holdings (NASDAQ:SBC) reported Q2:26 revenue of $49.2M, up 13% YoY, with operating profit rising 30% YoY. EGR expects AI clinic initiatives to add up to $15M in H2:26 revenue. The company has 287 clinics in Japan and is expanding globally. SBC had $185M in cash and $38M in debt, with a Debt/Book Equity ratio of 14%.

Emerging Growth Research reiterated a Buy rating on SBC Medical Group (NASDAQ: SBC) and raised its price target to $11.00. Q2:26 revenue grew 13% YoY to $49.2M, with net income rising to $10.7M. The company expects AI initiatives to add up to $15M in annual revenue and expanded its clinic network by 34 locations. SBC ended Q2:26 with $147M in net cash.

SBC Medical Group (NASDAQ:SBC) reported Q2 earnings call highlights. Management said customer numbers and spending per customer are rising, with aesthetic dermatology growing faster than the market. First-half transaction value increased 19% YoY. SBC plans multi-brand clinic expansion, AI-driven cost and growth initiatives, and targets 1,000 clinics by 2035. It expects JPY 15m full-year annual revenue from call-center and support changes.

SBC Medical Group Holdings (Nasdaq: SBC) reported Q2 FY2026 results for the three months ended June 30, 2026. Total revenue rose 13% to $49 million. Net income attributable to SBC Medical increased 335% to $11 million, and Adjusted EBITDA rose 32% to $20 million. The company cited AI-enabled fee increases and expects about $15 million in annual service-fee gains if fully realized.

SBC Medical Group Holdings Inc (SBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results Restructuring Complete, Growth Reaccelerates: Q2 Revenue Up 13%, Net Income Attributable to SBC Medical Up 335%, Adjusted EBITDA 1 Up 32% Year-over-Year. AI-Enabled Service Enhancements Drive Su